Stephen Rocamboli insider trades
Open-market stock purchases and sales by Stephen Rocamboli, Director at Esperion Therapeutics, Inc, from SEC Form 4 filings since Oct 29, 2019.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +109%.
Recent trades
No open-market trades in the last 12 months.